New protocol could reduce hepatitis C in the U.S. prison system by 95%
In the U.S. prison system, the prevalence of hepatitis C virus (HCV) infection is currently 10 times higher than the national average. And while new HCV treatment drugs are very effective, their high cost along with very limited healthcare budget in prisons impedes universal treatment in prisons. Now, new research in the INFORMS journal Operations Research, has identified new protocols that could substantially decrease HCV infection in the U.S. prison system.